Can we mitigate the psychological impacts of social isolation using behavioural activation? Long-term results of the UK BASIL urgent public health COVID-19 pilot randomised controlled trial and living systematic review.


Journal

Evidence-based mental health
ISSN: 1468-960X
Titre abrégé: Evid Based Ment Health
Pays: England
ID NLM: 100883413

Informations de publication

Date de publication:
12 2022
Historique:
received: 23 06 2022
accepted: 20 09 2022
pubmed: 13 10 2022
medline: 22 12 2022
entrez: 12 10 2022
Statut: ppublish

Résumé

Behavioural and cognitive interventions remain credible approaches in addressing loneliness and depression. There was a need to rapidly generate and assimilate trial-based data during COVID-19. We undertook a parallel pilot RCT of behavioural activation (a brief behavioural intervention) for depression and loneliness (Behavioural Activation in Social Isolation, the BASIL-C19 trial ISRCTN94091479). We also assimilate these data in a living systematic review (PROSPERO CRD42021298788) of cognitive and/or behavioural interventions. Participants (≥65 years) with long-term conditions were computer randomised to behavioural activation (n=47) versus care as usual (n=49). Primary outcome was PHQ-9. Secondary outcomes included loneliness (De Jong Scale). Data from the BASIL-C19 trial were included in a metanalysis of depression and loneliness. The 12 months adjusted mean difference for PHQ-9 was -0.70 (95% CI -2.61 to 1.20) and for loneliness was -0.39 (95% CI -1.43 to 0.65).The BASIL-C19 living systematic review (12 trials) found short-term reductions in depression (standardised mean difference (SMD)=-0.31, 95% CI -0.51 to -0.11) and loneliness (SMD=-0.48, 95% CI -0.70 to -0.27). There were few long-term trials, but there was evidence of some benefit (loneliness SMD=-0.20, 95% CI -0.40 to -0.01; depression SMD=-0.20, 95% CI -0.47 to 0.07). We delivered a pilot trial of a behavioural intervention targeting loneliness and depression; achieving long-term follow-up. Living meta-analysis provides strong evidence of short-term benefit for loneliness and depression for cognitive and/or behavioural approaches. A fully powered BASIL trial is underway. Scalable behavioural and cognitive approaches should be considered as population-level strategies for depression and loneliness on the basis of a living systematic review.

Sections du résumé

BACKGROUND
Behavioural and cognitive interventions remain credible approaches in addressing loneliness and depression. There was a need to rapidly generate and assimilate trial-based data during COVID-19.
OBJECTIVES
We undertook a parallel pilot RCT of behavioural activation (a brief behavioural intervention) for depression and loneliness (Behavioural Activation in Social Isolation, the BASIL-C19 trial ISRCTN94091479). We also assimilate these data in a living systematic review (PROSPERO CRD42021298788) of cognitive and/or behavioural interventions.
METHODS
Participants (≥65 years) with long-term conditions were computer randomised to behavioural activation (n=47) versus care as usual (n=49). Primary outcome was PHQ-9. Secondary outcomes included loneliness (De Jong Scale). Data from the BASIL-C19 trial were included in a metanalysis of depression and loneliness.
FINDINGS
The 12 months adjusted mean difference for PHQ-9 was -0.70 (95% CI -2.61 to 1.20) and for loneliness was -0.39 (95% CI -1.43 to 0.65).The BASIL-C19 living systematic review (12 trials) found short-term reductions in depression (standardised mean difference (SMD)=-0.31, 95% CI -0.51 to -0.11) and loneliness (SMD=-0.48, 95% CI -0.70 to -0.27). There were few long-term trials, but there was evidence of some benefit (loneliness SMD=-0.20, 95% CI -0.40 to -0.01; depression SMD=-0.20, 95% CI -0.47 to 0.07).
DISCUSSION
We delivered a pilot trial of a behavioural intervention targeting loneliness and depression; achieving long-term follow-up. Living meta-analysis provides strong evidence of short-term benefit for loneliness and depression for cognitive and/or behavioural approaches. A fully powered BASIL trial is underway.
CLINICAL IMPLICATIONS
Scalable behavioural and cognitive approaches should be considered as population-level strategies for depression and loneliness on the basis of a living systematic review.

Identifiants

pubmed: 36223980
pii: ebmental-2022-300530
doi: 10.1136/ebmental-2022-300530
pmc: PMC9811092
doi:

Types de publication

Journal Article Meta-Analysis Randomized Controlled Trial Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e49-e57

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: We have read the journal’s policy and the authors of this manuscript have the following competing interests. DE and CCG were committee members for the NICE Depression Guideline (update) Development Group between 2015 and 2022, and SiG was a member between 2015 and 2018. SiG, PC and DM are supported by the NIHR Yorkshire and Humberside Applied Research Collaboration (ARC) and DE is supported by the North East and North Cumbria ARCs. CCG is part funded by West Midland ARC.

Références

Lancet Public Health. 2020 Jan;5(1):e12-e13
pubmed: 31910976
J Psychiatr Res. 2018 Apr;99:69-75
pubmed: 29407289
Behav Ther. 2020 Jan;51(1):54-68
pubmed: 32005340
Lancet Psychiatry. 2021 Jan;8(1):48-57
pubmed: 33181096
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
J Clin Epidemiol. 2017 Nov;91:23-30
pubmed: 28912002
PLoS One. 2014 Jun 17;9(6):e100100
pubmed: 24936656
Psychother Psychosom. 2021;90(5):351-358
pubmed: 34182552
J Ment Health. 2019 Aug;28(4):410-418
pubmed: 29722574
Eur J Prev Cardiol. 2018 Sep;25(13):1387-1396
pubmed: 30068233
Int J Psychol. 2018 Oct;53(5):373-378
pubmed: 27704544
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
PLoS One. 2022 Mar 24;17(3):e0263856
pubmed: 35324908
Am J Geriatr Psychiatry. 2020 Jul;28(7):698-708
pubmed: 32238297
Soc Psychiatry Psychiatr Epidemiol. 2017 Jun;52(6):627-638
pubmed: 28528389
Int J Nurs Sci. 2016 Sep;3(3):242-251
pubmed: 29082303
Lancet Healthy Longev. 2021 Feb;2(2):e54-e55
pubmed: 36098152
Lancet Public Health. 2020 Jan;5(1):e62-e70
pubmed: 31910981
Lancet Psychiatry. 2021 Aug;8(8):647-650
pubmed: 34087112
Brain Behav Immun. 2012 Oct;26(7):1095-101
pubmed: 22820409
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
Int J Geriatr Psychiatry. 2011 Dec;26(12):1211-20
pubmed: 21308789
Br J Psychiatry. 2017 Nov;211(5):274-279
pubmed: 28982660
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
BMJ. 2020 Jul 30;370:m2925
pubmed: 32732314
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
PLoS Med. 2021 Oct 12;18(10):e1003779
pubmed: 34637450
JAMA. 2017 Feb 21;317(7):728-737
pubmed: 28241357
Am J Geriatr Psychiatry. 2021 Aug;29(8):771-776
pubmed: 34130906
Am J Geriatr Psychiatry. 2022 Feb;30(2):197-207
pubmed: 34266750
Int J Environ Res Public Health. 2019 Apr 11;16(7):
pubmed: 30979042
Mil Med. 2004 Oct;169(10):814-20
pubmed: 15532347
JAMA Netw Open. 2022 Apr 1;5(4):e227629
pubmed: 35452109
Internet Interv. 2020 Jan 17;19:100301
pubmed: 32071885
Lancet Psychiatry. 2020 Jul;7(7):567-568
pubmed: 32502467
Lancet Public Health. 2021 Jun;6(6):e365-e373
pubmed: 33894138
Am J Geriatr Psychiatry. 2022 Dec;30(12):1313-1323
pubmed: 35680539
Clin Psychol Rev. 2021 Aug;88:102066
pubmed: 34339939

Auteurs

Elizabeth Littlewood (E)

Health Sciences, University of York, York, UK.

Dean McMillan (D)

Health Sciences, University of York, York, UK.
Centre for Health and Population Science, Hull York Medical School, Hull, UK.

Carolyn Chew Graham (C)

School of Medicine, Keele University, Keele, UK.

Della Bailey (D)

Health Sciences, University of York, York, UK.

Samantha Gascoyne (S)

Health Sciences, University of York, York, UK.

Claire Sloane (C)

Health Sciences, University of York, York, UK.

Lauren Burke (L)

Health Sciences, University of York, York, UK.

Peter Coventry (P)

Health Sciences, University of York, York, UK.
York Environmental Sustainability Institute, University of York, York, UK.

Suzanne Crosland (S)

Health Sciences, University of York, York, UK.

Caroline Fairhurst (C)

Health Sciences, University of York, York, UK.

Andrew Henry (A)

Health Sciences, University of York, York, UK.

Catherine Hewitt (C)

Health Sciences, University of York, York, UK.

Kalpita Baird (K)

Health Sciences, University of York, York, UK.

Eloise Ryde (E)

Health Sciences, University of York, York, UK.
Research and Development Unit, Tees Esk and Wear Valleys NHS Foundation Trust, Darlington, UK.

Leanne Shearsmith (L)

Faculty of Medicine and Health, University of Leeds, Leeds, UK.

Gemma Traviss-Turner (G)

Faculty of Medicine and Health, University of Leeds, Leeds, UK.

Rebecca Woodhouse (R)

Health Sciences, University of York, York, UK.

Judith Webster (J)

Research and Development Unit, Tees Esk and Wear Valleys NHS Foundation Trust, Darlington, UK.

Nick Meader (N)

Faculty of Medical Sciences, University of Newcastle, Newcastle upon Tyne, UK.

Rachel Churchill (R)

Cochrane Common Mental Disorders Group, University of York, York, UK.

Elizabeth Eddy (E)

Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.

Paul Heron (P)

Health Sciences, University of York, York, UK.

Nisha Hicklin (N)

Department of Psychology, Royal Holloway University of London, Egham, UK.

Roz Shafran (R)

PPP, University College London Institute of Child Health, London, UK.
Paediatric Psychology Services, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Osvaldo Almeida (O)

UWA Medical School, The University of Western Australia, Perth, Western Australia, Australia.

Andrew Clegg (A)

Faculty of Medicine and Health, University of Leeds, Leeds, UK.
Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford, UK.

Tom Gentry (T)

Health and Care Policy, Age UK, London, UK.

Andrew Hill (A)

Faculty of Medicine and Health, University of Leeds, Leeds, UK.

Karina Lovell (K)

Division of Nursing, Midwifery and Social Work, The University of Manchester, Manchester, UK.

Sarah Dexter-Smith (S)

Research and Development Unit, Tees Esk and Wear Valleys NHS Foundation Trust, Darlington, UK.

David Ekers (D)

Health Sciences, University of York, York, UK.
Research and Development Unit, Tees Esk and Wear Valleys NHS Foundation Trust, Darlington, UK.

Simon Gilbody (S)

Health Sciences, University of York, York, UK simon.gilbody@york.ac.uk.
Centre for Health and Population Sciences, Hull York Medical School, York, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH